Aragen Life Science, formerly GVK Biosciences, secures a $100 million investment from healthcare-focused private equity fund Quadria Capital. The investment will support Aragen’s strategic expansion and infrastructure development to meet growing demand for outsourcing services from US and Europe innovators. This move positions Aragen strongly in the pharmaceutical outsourcing market, enhancing its capabilities and accelerating program delivery.
Related Posts
Navigating Budget 2025: Implications for taxpayers and markets
- staff
- February 3, 2025
- 0
Analysing Budget 2025 and how finance minister Nirmala Sitharaman’s budget has had a fallout on markets; how can investors balance risks in evolving financial landscape
Gold price outlook: Is precious metal still a good investment bet post import duty cut? Here’s why you shouldn’t dismiss it!
The recent reduction of gold import duty from 15% to 6% resulted in an 8% drop in domestic gold prices, affecting gold ETFs and sovereign […]
Run-up to Budget 2025: Need for some deduction-related relief in new regime
- staff
- January 9, 2025
- 0
India’s Budget 2025 may potentially abolish the old tax regime. The new tax regime, default since 2020-21, offers simplified, lower tax rates with fewer benefits. […]